TransMedics Group Inc TMDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
-
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
-
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
-
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
-
TransMedics to Present at Upcoming September Investor Conferences
-
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
-
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
-
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
Trading Information
- Previous Close Price
- $78.64
- Day Range
- $77.14–80.85
- 52-Week Range
- $60.11–156.00
- Bid/Ask
- $77.01 / $80.00
- Shares Outstanding
- 34.68M
- Market Cap
- $2.77B
- Volume/Avg
- 1M / 816,563
Key Statistics
- Price/Earnings (Normalized)
- 20.39
- Price/Sales
- 4.52
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 898
- Website
- https://www.transmedics.com
Valuation
|
Metric
|
TMDX
|
|---|---|
Price/Earnings (Normalized) | 20.39 |
Price/Book Value | 5.26 |
Price/Sales | 4.52 |
Price/Cash Flow | 18.87 |
Price/Earnings
TMDX
Financial Strength
|
Metric
|
TMDX
|
|---|---|
Quick Ratio | 5.87 |
Current Ratio | 6.62 |
Interest Coverage | 4.37 |
Quick Ratio
TMDX
Profitability
|
Metric
|
TMDX
|
|---|---|
Return on Assets (Normalized) | 15.63% |
Return on Equity (Normalized) | 42.02% |
Return on Invested Capital (Normalized) | 18.13% |
Return on Assets
TMDX
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|#nm^R^ | LOCK|Vft?# | $169B | |||
| Medtronic PLC
MDT
| LOCK|YB#!NV | LOCK|>x?#L | $110B | |||
| Stryker Corp
SYK
| LOCK|z<^&Q@! | LOCK|#p | $106B | |||
| Boston Scientific Corp
BSX
| LOCK|@Tw#%# | LOCK|Pk&Dl | $62B | |||
| Edwards Lifesciences Corp
EW
| LOCK|jWLmQ<Q | LOCK|><z<? | $49B | |||
| DexCom Inc
DXCM
| LOCK|>y!!$$R | LOCK|$rbTN | $32B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|N&MF^# | LOCK|YkF | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|#@ | LOCK|DJ | $23B | |||
| Steris PLC
STE
| LOCK|Qdw@<b | LOCK|?f$vM | $20B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|Kt&#$pCF | LOCK|f%& | $17B |
United States